Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

EW
Edwards Lifesciences Corp
stock NYSE

At Close
Apr 7, 2026 3:59:53 PM EDT
80.85USD-0.419%(-0.34)4,011,656
76.66Bid   85.36Ask   8.70Spread
Pre-market
Apr 2, 2026 9:16:30 AM EDT
78.16USD-3.734%(-3.03)0
After-hours
Apr 7, 2026 4:00:30 PM EDT
80.84USD-0.012%(-0.01)6,658
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
01:02PM EST  Where Edwards Lifesciences Stands With Analysts   Benzinga
07:56AM EST  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $136   Benzinga
07:14AM EST  Raymond James Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $126   Benzinga
04:33AM EST  SVB Leerink Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $130   Benzinga
Jan 26, 2022
05:17PM EST  CORRECTION: Edwards Lifesciences Sees FY22 Adj. EPS $2.50-$2.65   Benzinga
05:15PM EST  Edwards Lifesciences Sees Q1 Adj. EPS $0.54-$0.62 vs $0.60 Est., Sales $1.27B-$1.35B vs $1.36B Est.; Sees FY22 Adj. EPS $2.50-$2.65 vs $2.58 Est., Sales $5.5B-$6B vs $5.82B Est.   Benzinga
05:02PM EST  Edwards Lifesciences: Q4 Earnings Insights   Benzinga
04:37PM EST  Edwards Lifesciences Sees Q1 Adj. EPS $0.54-$0.62 vs $0.60 Est., Sales $1.27B-$1.35B vs $1.36B Est.; Sees FY22 Adj. EPS $2.65-$2.22 vs $2.58 Est., Sales $5.5B-$6B vs $5.82B Est.   Benzinga
04:33PM EST  UPDATE: Edwards Lifesciences Q4 Adj. EPS $0.51   Benzinga
04:33PM EST  Edwards Lifesciences Q4 Adj. EPS $0.51 Misses $0.55 Estimate, Sales $1.33B Miss $1.36B Estimate   Benzinga
04:31PM EST  Edwards Lifesciences Q4 EPS $0.53 Misses $0.55 Estimate, Sales $1.33B Miss $1.36B Estimate   Benzinga
04:26PM EST  Edwards Lifesciences Corp. (EW) revealed earnings for its fourth quarter that increased from last year but missed the Street estimates.   RTTNews
04:15PM EST  EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS   PR Newswire
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
03:59AM EST  Earnings Scheduled For January 26, 2022   Benzinga
Jan 25, 2022
10:07AM EST  Preview: Edwards Lifesciences's Earnings   Benzinga
Jan 23, 2022
11:03AM EST  The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More   Benzinga
Jan 21, 2022
06:21AM EST  SVB Leerink Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $132   Benzinga
Jan 19, 2022
07:05AM EST  EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022   PR Newswire
Jan 10, 2022
11:12AM EST  $100 Invested In This Stock 10 Years Ago, Would Be Worth This Much   Benzinga
Jan 7, 2022
01:11PM EST  Where Edwards Lifesciences Stands With Analysts   Benzinga
01:08PM EST  Credit Suisse Maintains Outperform on Edwards Lifesciences, Raises Price Target to $140   Benzinga
01:04PM EST  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $148   Benzinga
Jan 5, 2022
08:10AM EST  EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE   PR Newswire
Dec 20, 2021
09:29AM EST  Edwards Lifesciences (EW) said it received approval from the U.S. Food and Drug Administration for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for patients with severe pulmonary regurgitation.   RTTNews
09:16AM EST  Edwards Lifesciences Gets FDA Approval For SAPIEN 3 With Alterra For Patients With Severe Pulmonary Regurgitation   RTTNews
09:16AM EST  Edwards Receives FDA Approval For Sapien 3 With Alterra Prestent For Transcatheter Pulmonic Valve Replacement   Benzinga
09:16AM EST  EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR   PR Newswire
Dec 17, 2021
10:18AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021   Benzinga
05:05AM EST  JP Morgan Upgrades Edwards Lifesciences to Overweight, Announces $140 Price Target   Benzinga
Dec 15, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021   Benzinga
07:26AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
07:03AM EST  Citigroup Upgrades Edwards Lifesciences to Buy, Raises Price Target to $142   Benzinga
Dec 10, 2021
12:41PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021   Benzinga
07:51AM EST  10 Biggest Price Target Changes For Friday   Benzinga
05:05AM EST  RBC Capital Initiates Coverage On Edwards Lifesciences with Outperform Rating, Announces Price Target of $142   Benzinga
04:45AM EST  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $134   Benzinga
Dec 9, 2021
09:51PM EST  Where Edwards Lifesciences Stands With Analysts   Benzinga
09:50PM EST  10 Biggest Price Target Changes For Thursday   Benzinga
09:47PM EST  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $144   Benzinga
09:46PM EST  Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $133   Benzinga
09:44PM EST  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $135   Benzinga
Dec 8, 2021
09:58AM EST  Hearing Edwards Lifesciences CEO To Appear On Jim Cramer's 'Mad Money' Wednesday Evening   Benzinga
09:06AM EST  Edwards Lifesciences Reaffirms FY21 Guidance   Benzinga
09:05AM EST  Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference   PR Newswire
Dec 6, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021   Benzinga
06:17AM EST  Wells Fargo Upgrades Edwards Lifesciences to Overweight, Announces $126 Price Target   Benzinga
Nov 8, 2021
05:42AM EST  Edwards' Transcatheter Tricuspid Replacement System Shows Favorable Patient Outcomes   Benzinga
Nov 6, 2021
01:47PM EDT  Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement   PR Newswire
Nov 5, 2021
11:20AM EDT  TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy   PR Newswire
Oct 28, 2021
12:23PM EDT  Expert Ratings For Edwards Lifesciences   Benzinga
09:17AM EDT  Credit Suisse Maintains Outperform on Edwards Lifesciences, Raises Price Target to $130   Benzinga
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
07:37AM EDT  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $127   Benzinga
Oct 27, 2021
06:10PM EDT  Recap: Edwards Lifesciences Q3 Earnings   Benzinga
04:29PM EDT  Edwards Lifesciences Q3 EPS $0.54 Vs. $0.52 Year Ago   RTTNews
04:25PM EDT  Edwards Lifesciences Corp. (EW) announced earnings for its third quarter that rose from last year.   RTTNews
04:20PM EDT  Edwards Lifesciences Sees Q4 Adj. EPS $0.53-$0.59 vs $0.56 Estimate, Sales $1.3B-$1.38B vs $1.41B Est.   Benzinga
04:20PM EDT  Edwards Lifesciences Sees FY21 Adj. EPS At High End Of Previously-Issued $2.07-$2.27 Range vs $2.26 Estimate, Sales $5.2B-$5.4B vs $5.32B Est.   Benzinga
04:18PM EDT  Edwards Lifesciences Q3 EPS $0.54 Beats $0.53 Estimate, Sales $1.31B Miss $1.32B Estimate   Benzinga
04:16PM EDT  Edwards Lifesciences Reports Third Quarter Results   PR Newswire
03:43AM EDT  Earnings Scheduled For October 27, 2021   Benzinga
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 20, 2021
07:05AM EDT  Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021   PR Newswire
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 21, 2021
12:30PM EDT  Where Edwards Lifesciences Stands With Analysts   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 3, 2021
10:29AM EDT  Goldman Sachs Maintains Neutral on Edwards Lifesciences, Raises Price Target to $105   Benzinga
Aug 2, 2021
01:21PM EDT  Expert Ratings for Edwards Lifesciences   Benzinga
07:51AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
05:02AM EDT  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $122   Benzinga
Jul 30, 2021
02:00PM EDT  UPDATE: Canaccord On Edward Price Target Raise Post-Earnings: Firm Sees Market Dominance In Transcatheter Aortic Valve Replacements & 'Large Future Opportunity' In Transcatheter Mitral & Tricuspid Therapies; Notes Waning Covid Effects On Procedure Volumes   Benzinga
01:55PM EDT  Canaccord Genuity Reaffirms Buy Rating On Edward Lifesciences And Raises Price Target From $103 To $124   Benzinga
12:15PM EDT  Expert Ratings for Edwards Lifesciences   Benzinga
12:14PM EDT  What 16 Analyst Ratings Have To Say About Edwards Lifesciences   Benzinga
12:00PM EDT  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $135   Benzinga
10:51AM EDT  Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $123   Benzinga
10:21AM EDT  Deutsche Bank Maintains Hold on Edwards Lifesciences, Raises Price Target to $113   Benzinga
10:10AM EDT  Jefferies Maintains Buy on Edwards Lifesciences, Raises Price Target to $130   Benzinga
10:04AM EDT  UPDATE: Credit Suisse On Edwards Price Target Raise Post-Earnings: Firm Highlights Robust TAVR Beat With Strength Both In The U.S. & Internationally As Sales Were Up 50% Y/Y Domestically; Notes Gross Margin Up 150 bps Y/Y Given Profitable Product Mix   Benzinga
10:03AM EDT  Canaccord Genuity Maintains Buy on Edwards Lifesciences, Raises Price Target to $124   Benzinga
09:52AM EDT  Edwards Lifesciences shares were trading higher after the company reported better-than-expected Q2 EPS and sales results.   Benzinga
09:10AM EDT  Credit Suisse Maintains Outperform on Edwards Lifesciences, Raises Price Target to $126   Benzinga
08:14AM EDT  Edwards Lifesciences Beats Q2 Earnings On Demand Recovery, Boosts FY2021 Guidance; Analysts Raise Price Target   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:41AM EDT  Wells Fargo Maintains Equal-Weight on Edwards Lifesciences, Raises Price Target to $115   Benzinga
04:48AM EDT  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $130   Benzinga
Jul 29, 2021
06:09PM EDT  Edwards Lifesciences Corp. (EW) Thursday lifted its outlook for the full year 2021.   RTTNews
04:58PM EDT  UPDATE: Edwards Lifesciences Raises FY21 EPS Guidance To High End Of $2.07-$2.27 vs $2.21 Estimate   Benzinga
04:57PM EDT  Edwards Lifesciences Q2 Adj. EPS $0.64 Beats $0.55 Estimate, Sales $1.38B Beat $1.28B Estimate; Raises Guidance   Benzinga
04:19PM EDT  Edwards Lifesciences Reports Q2 EPS Of $0.78 Vs. Loss Per Share Of $0.20 Last Year   RTTNews
04:16PM EDT  Edwards Lifesciences Reports Second Quarter Results   PR Newswire
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 22, 2021
03:15PM EDT  Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3   PR Newswire
07:06AM EDT  Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021   PR Newswire
Jul 20, 2021
12:12PM EDT  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $125   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 25, 2021
07:32AM EDT  The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs   Benzinga
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 16, 2021
08:20AM EDT  The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO   Benzinga
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 1, 2021
04:16PM EDT  Edwards Receives FDA Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff   Benzinga
04:15PM EDT  Edwards Receives Clearance For Hypotension Prediction Index Software For   PR Newswire
May 25, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021   Benzinga
06:43AM EDT  Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110   Benzinga
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 18, 2021
04:16PM EDT  Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs   PR Newswire
04:16PM EDT  Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With   PR Newswire
May 5, 2021
09:27AM EDT  Edwards Lifesciences Says All Eight Director Nominees Were Elected As Directors; Plans Addl $1 Bln Share Repurchase   RTTNews
09:27AM EDT  Edwards Announces Updates From Annual Meeting   PR Newswire
Apr 23, 2021
07:28AM EDT  The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
03:01PM EDT  Providence Partners With Edwards Lifesciences, Cities of Irvine, Santa Ana, Costa Mesa, And Tustin To Open Two Free Mass COVID-19 Vaccination Clinics   Benzinga
03:01PM EDT  Providence Partners with Edwards Lifesciences, Cities of Irvine, Santa Ana,   PR Newswire
10:45AM EDT  Canaccord Genuity Maintains Buy on Edwards Lifesciences, Raises Price Target to $103   Benzinga
10:37AM EDT  Price Over Earnings Overview: Edwards Lifesciences   Benzinga
10:13AM EDT  Shares of Edwards Lifesciences Corp. (EW) reached an all-time high of $94.00 Wednesday morning, and are currently trading at $93.39, up $3.76 or 4.20%, with trading volume rising over 1.22 million versus an average volume of 2.75 million shares.   RTTNews
08:48AM EDT  Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105   Benzinga
08:43AM EDT  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $108   Benzinga
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
07:20AM EDT  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $101   Benzinga
Apr 20, 2021
05:14PM EDT  Shares of Edwards Lifesciences Corp. (EW) gained nearly 4% in extended trading session on Tuesday after the company's first-quarter earnings and revenues trumped Wall Street estimates. The company also lifted its earnings guidance for the full year 2021.   RTTNews
04:38PM EDT  Edwards Lifesciences Corp. (EW) reported earnings for its first quarter that rose from last year.   RTTNews
04:29PM EDT  Edwards Lifesciences: Q1 Earnings Insights   Benzinga
04:24PM EDT  Edwards Lifesciences Corp. (EW) released earnings for its first quarter that advanced from last year.   RTTNews
04:18PM EDT  Edwards Lifesciences Q1 EPS $0.54 Vs $0.49 Last Year   RTTNews
04:17PM EDT  Edwards Lifesciences Sees Q2 Adj. EPS $0.54-$0.60 vs $0.52 Est., Sales $1.25B-$1.33B vs $1.25B Est.; Raises FY21 Adj. EPS $2.00-$2.20 To $2.07-$2.27 vs $2.13 Est., Sees Sales $4.9B-$5.3B vs $5.08B Est.   Benzinga
04:16PM EDT  Edwards Lifesciences Q1 EPS $0.54 Beats $0.47 Estimate, Sales $1.22B Beat $1.16B Estimate   Benzinga
04:15PM EDT  Edwards Lifesciences Reports First Quarter Results   PR Newswire
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
04:02AM EDT  Earnings Scheduled For April 20, 2021   Benzinga
Apr 19, 2021
10:15AM EDT  Edwards Lifesciences's Earnings Outlook   Benzinga
Apr 15, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021   Benzinga
07:08AM EDT  Atlantic Equities Initiates Coverage On Edwards Lifesciences with Neutral Rating, Announces Price Target of $85   Benzinga
Apr 13, 2021
07:05AM EDT  Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021   PR Newswire
Apr 5, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2021   Benzinga
06:59AM EDT  Evercore ISI Group Upgrades Edwards Lifesciences to Outperform   Benzinga
Mar 2, 2021
08:23AM EST  Cramer Shares His Thoughts On Penn National Gaming, Snap, More   Benzinga
Jan 31, 2021
07:57PM EST  Edwards Lifesciences' (EW) bioprosthetic surgical aortic valve with its RESILIA tissue platform showed favorable safety and hemodynamic performance through a median of five years follow-up, as per new data from the COMMENCE clinical trial.   RTTNews
04:51PM EST  Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy   PR Newswire
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 27, 2021
04:50PM EST  Recap: Edwards Lifesciences Q4 Earnings   Benzinga
04:35PM EST  Edwards Lifesciences Corp. (EW) revealed earnings for its fourth quarter that advanced from the same period last year.   RTTNews
04:18PM EST  Edwards Lifesciences Sees FY21 Adj. EPS $2-$2.20 vs $2.15 Estimate, Sales $4.9B-$5.3B vs $5.09B Est.   Benzinga
04:18PM EST  Edwards Lifesciences Q4 EPS $0.49 Vs.$0.44 Year Ago   RTTNews
04:18PM EST  Edwards Lifesciences Sees Q1 Adj. EPS $0.43-$0.50 vs $0.50 Estimate, Sales $1.1B-$1.2B vs $1.21B Est.   Benzinga
04:17PM EST  Edwards Lifesciences Q4 Adj. EPS $0.50 Misses $0.53 Estimate, Sales $1.19B Beat $1.19B Estimate   Benzinga
04:16PM EST  Edwards Lifesciences Reports Fourth Quarter Results   PR Newswire
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
04:09AM EST  Earnings Scheduled For January 27, 2021   Benzinga
Jan 26, 2021
10:32AM EST  Edwards Lifesciences's Earnings: A Preview   Benzinga
Jan 23, 2021
09:14AM EST  The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More   Benzinga
Jan 13, 2021
07:05AM EST  Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021   PR Newswire
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 21, 2020
09:14AM EST  Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease   Benzinga
09:10AM EST  Edwards Lifesciences Says First Patient Treated In RESTORE Clinical Trial   RTTNews
09:05AM EST  Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally   PR Newswire
Dec 18, 2020
02:01PM EST  Edwards SAPIEN 3 TAVI Receives Expanded Approval In Canada   RTTNews
Dec 16, 2020
11:37AM EST  Edwards Lifesciences shares were trading lower after Citigroup downgraded the stock from Buy to Neutral.   Benzinga
11:25AM EST  Benzinga's Top Upgrades, Downgrades For December 16, 2020   Benzinga
09:28AM EST  Citigroup Downgrades Edwards Lifesciences to Neutral   Benzinga
Dec 14, 2020
09:50AM EST  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99   Benzinga
Dec 11, 2020
10:24AM EST  Canaccord Genuity Maintains Buy on Edwards Lifesciences, Raises Price Target to $94   Benzinga
09:32AM EST  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $96   Benzinga
08:36AM EST  10 Biggest Price Target Changes For Friday   Benzinga
05:11AM EST  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $106   Benzinga
Dec 10, 2020
10:01AM EST  Edwards Lifesciences Corp. (EW) presents long-term strategic initiatives and growth outlook at its annual investor conference. It expects 2021 adjusted earnings per share to be in the range of $2.00 - $2.20. Analysts polled by Thomson Reuters expect the company to report earnings of $2.22 per share for fiscal year 2021. Analysts' estimates typically exclude special items.   RTTNews
09:08AM EST  Edwards Lifesciences Projects 2021 Global Sales Of $4.9 Bln-$5.3 Bln; Underlying Growth In Mid-teens   RTTNews
09:05AM EST  Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference   PR Newswire
Nov 18, 2020
07:47AM EST  Wells Fargo Maintains Equal-Weight on Edwards Lifesciences, Raises Price Target to $87   Benzinga
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Oct 22, 2020
08:28AM EDT  Credit Suisse Maintains Outperform on Edwards Lifesciences, Raises Price Target to $97   Benzinga
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
07:18AM EDT  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $90   Benzinga
Oct 21, 2020
06:39PM EDT  16 Stocks Moving In Wednesday's After-Hours Session   Benzinga
04:43PM EDT  Edwards Lifesciences: Q3 Earnings Insights   Benzinga
04:28PM EDT  Edwards Lifesciences Q3 EPS $0.52 Vs. $0.43 Year Ago   RTTNews
04:23PM EDT  Edwards Lifesciences Corp. (EW) reported earnings for its third quarter that advanced from last year.   RTTNews
04:18PM EDT  Edwards Lifesciences Raises FY20 Adj. EPS Guidance From $1.75-$1.95 To $1.85-$1.95 vs $1.84 Est.   Benzinga
04:17PM EDT  Edwards Lifesciences Q3 Adj. EPS $0.51 Beats $0.44 Estimate, Sales $1.14B Beat $1.08B Estimate   Benzinga
04:15PM EDT  Edwards Lifesciences Reports Third Quarter Results   PR Newswire
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
04:07AM EDT  Earnings Scheduled For October 21, 2020   Benzinga
Oct 16, 2020
11:34AM EDT  A Look Into Edwards Lifesciences Price Over Earnings   Benzinga
Oct 14, 2020
09:51AM EDT  Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $93   Benzinga
Oct 12, 2020
10:21AM EDT  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100   Benzinga
Oct 7, 2020
10:05AM EDT  Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020   PR Newswire
Sep 11, 2020
12:18PM EDT  Wolfe Research Initiates Coverage On Edwards Lifesciences with Underperform Rating   Benzinga
Jul 24, 2020
11:02AM EDT  Stifel Maintains Buy on Edwards Lifesciences, Raises Price Target to $90   Benzinga
10:46AM EDT  Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised 2020 EPS expectations.   Benzinga
09:54AM EDT  Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $91   Benzinga
09:48AM EDT  P/E Ratio Insights for Edwards Lifesciences   Benzinga
09:41AM EDT  Canaccord Genuity Maintains Buy on Edwards Lifesciences, Raises Price Target to $89   Benzinga
09:30AM EDT  Jefferies Maintains Buy on Edwards Lifesciences, Raises Price Target to $95   Benzinga
08:36AM EDT  Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $88   Benzinga
08:26AM EDT  Credit Suisse Maintains Outperform on Edwards Lifesciences, Raises Price Target to $92   Benzinga
07:59AM EDT  Raymond James Maintains Outperform on Edwards Lifesciences, Raises Price Target to $88   Benzinga
06:13AM EDT  A Peek Into The Markets: US Stock Futures Down Following Thursday's Sell-Off   Benzinga
04:51AM EDT  SVB Leerink Maintains Outperform on Edwards Lifesciences, Raises Price Target to $95   Benzinga
Jul 23, 2020
04:49PM EDT  Edwards Lifesciences: Q2 Earnings Insights   Benzinga
04:41PM EDT  Edwards Lifesciences Corp. (EW) said the company now expects full-year 2020 adjusted earnings per share of $1.75 to $1.95 on a post-split basis, versus previous guidance of $1.58 to $1.75, or on a pre-split basis, $4.75 to $5.25. Overall, 2020 sales guidance continues to be $4.0 to $4.5 billion.   RTTNews
04:21PM EDT  Edwards Lifesciences Q2 Loss/share $0.20 Vs. Profit $0.38 Year Ago   RTTNews
04:16PM EDT  Edwards Raises FY20 Adj. EPS Guidance From $1.58-$1.75 To $1.75-$1.95 vs $1.63 Estimate   Benzinga
04:16PM EDT  Edwards Lifesciences Reports Second Quarter Results   PR Newswire
04:15PM EDT  Edwards Lifesciences Q2 Adj. EPS $0.34 Beats $0.17 Estimate, Sales $925.00M Beat $789.42M Estimate   Benzinga
04:30AM EDT  Earnings Scheduled For July 23, 2020   Benzinga
Jul 15, 2020
08:44AM EDT  Edwards Lifesciences Corp. (EW) has received approval from the U.S. FDA for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. The KONECT device comes with the advanced RESILIA tissue, which incorporates integrity-preservation technology that may help improve valve durability.   RTTNews
08:33AM EDT  Edwards Lifesciences Gets FDA Approval For KONECT RESILIA Aortic Valved Conduit   RTTNews
08:33AM EDT  Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries   Benzinga
08:32AM EDT  Edwards Lifesciences Names Paul LaViolette To Board   RTTNews
08:31AM EDT  Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex   PR Newswire
08:31AM EDT  Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors   PR Newswire
Jul 13, 2020
04:17PM EDT  Abbott Reports Deal For Global Transcatheter Litigation Settlement With Edwards Lifesciences, Terms Confidential   Benzinga
04:16PM EDT  Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott   RTTNews
04:15PM EDT  Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC